KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Cash and Short Term Investments

Last Annual Value

117.98M

3-Year CAGR

238%

5-Year CAGR

-20%

10-Year CAGR

-10%

KT

Kalaris Therapeutics Inc Competitors Analysis of Cash and Short Term Investments

KLRS · NASDAQ
CompanyCash and Short Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
117.98M
233.9%-13.8%N/A 
69.64M
-13.0%-18.0%3.0%
108.01M
12.0%-7.7%N/A
78.06M
-15.8%-21.9%N/A
66.00M
65.9%5.9%N/A
160.80M
-16.0%8.3%N/A
125.69M
9.2%-16.3%-5.5%
44.79M
-37.4%-34.2%N/A
81.54M
34.5%-3.1%N/A
48.91M
-20.2%-11.3%N/A
125.89M
-8.1%6.0%15.0%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66